UAE adopts Memrylo for erythema multiforme
The Emirates Pharmaceutical Authority has announced its approval of the drug "Memeryllo" (Ruxolitinib) for the treatment of adults with polycythemia vera, a rare blood disorder caused by abnormal production of red blood cells, which increases the risk of blood clots. The medication helps lower red blood cell levels and effectively manages the condition. This approval, which is the second globally, represents an important step to enhance the treatment options available to Emirati patients and supports the UAE's position in providing advanced therapies for rare diseases. "Memeryllo" is supplied in vials containing a sterile powder that must be reconstituted before use and is dispensed under the supervision of a medical professional.
Notice: This Is an AI-Generated Summary
Comments (0)